CATX
Perspective Therapeutics, Inc.
$3.76
+4.44%
2026-05-08
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.
Key Fundamentals
Forward P/E
-3.13
EPS (TTM)
$-1.41
ROE
-41.6%
Revenue Growth (YoY)
-43.4%
Profit Margin
0.0%
Debt/Equity
1.57
Price/Book
1.32
Beta
1.76
Market Cap
$418.4M
Avg Volume (10D)
1.9M
Recent Breakout Signals
No recent breakout signals detected for CATX.
Recent Price Range (60 Days)
60D High
$5.90
60D Low
$3.52
Avg Volume
1.5M
Latest Close
$3.76
Get breakout alerts for CATX
Sign up for Breakout Scanner to receive daily notifications when CATX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Perspective Therapeutics, Inc. (CATX) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors CATX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CATX operates in the Healthcare sector within the Medical Devices industry. Data is provided for informational purposes only and does not constitute financial advice.